RRMS patients have an increased expression of IL-11+ CD14+ monocytes, IL-11+ and IL-11R+ CD4+ cells, and IL-11R+ neutrophils in comparison to matched healthy control patients [72], so the blockade of the IL-11R receptor by eUb could be explored in preclinical research. This evidence concerns the gene IL11 and relapsing-remitting multiple sclerosis.